Fritillaria thunergii medicine composition for treating acute leukemia and its new use

Abstract

The present invention discloses a drug for treating acute leukemia and refractory acute leukemia, the components of the pharmaceutical raw materials of the drug composition are: 5 to 20 parts by weight of thunberg fritillary bulb, 5 to 20 parts by weight of fourstamen stephania root and 2 to 12 parts by weight of Szechuan lovage rhizome. The present invention provides an application of the thunberg fritillary bulb composition in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia; the present invention carries out a large amount of experiments, which takes the clinical remission rate as the clinical efficacy evaluation index and takes the heart, liver, renal function etc. as the safety indexes and the detection indexes, the results prove that the thunberg fritillary bulb composition has better clinical efficacy in the adjuvant chemotherapy to improve the clinical efficacy of the refractory acute leukemia and also has the better clinical medication safety.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating acute leukemia and refractory acute leukemia. Background technique [0002] Leukemia (acute leukemia, AL) is a common malignant tumor disease of hematopoietic tissue. Its main feature is abnormal proliferation of white blood cells, and the lesion involves bone marrow, liver, spleen, lymph nodes, and other tissues and organs. Because the proliferating leukemia cells have the biological characteristics of malignant tumors, it is also called "blood cancer". The natural development process of leukemia is irreversible, and most patients with leukemia who are ineffective or untreated die of severe complications caused by malignant proliferation of leukemia cells. According to relevant data, the incidence of leukemia is about 3-4 / 100,000, accounting for 5% of the total incidence of malignant tumors. There are more than 40,000 new leukemia patie...

AI Technical Summary

Problems solved by technology

② Sequential application of hematopoietic growth factors and chemotherapeutic drugs: It has been reported that 12 cases of relapsed adult ALL were treated with the FLAG regimen composed of fludarabine combined with Ara-C and G-CSF. The remaining 10 cases all achieved complete remission (83%), but the complete remission period was not ideal, with a median of 25.5 weeks

[0010] At present, there is no ideal therapeutic drug or method that has been widely used in clinical practice. The main reasons are as follows: ① most of the existing reversal agents are "substitutes", that is, old drugs are used for new purposes, and reversal of drug resistance is often not the alternative. The main function is that there are many contraindications for clinical use, and the toxicity and side effects are large; ②biological agents are unstable in the body, it is difficult to act on target cells, and there are many toxic and side effects; ③Clinical drug resistance often involves multiple mechanisms at the same time, and only a single mechanism is involved Active reversal agents have difficulty exerting therapeutic effects

Images